5UEZ

BRD4_BD2_A-1342843


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.51 Å
  • R-Value Free: 0.204 
  • R-Value Work: 0.182 
  • R-Value Observed: 0.183 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.1 of the entry. See complete history


Literature

Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.

Wang, L.Pratt, J.K.Soltwedel, T.Sheppard, G.S.Fidanze, S.D.Liu, D.Hasvold, L.A.Mantei, R.A.Holms, J.H.McClellan, W.J.Wendt, M.D.Wada, C.Frey, R.Hansen, T.M.Hubbard, R.Park, C.H.Li, L.Magoc, T.J.Albert, D.H.Lin, X.Warder, S.E.Kovar, P.Huang, X.Wilcox, D.Wang, R.Rajaraman, G.Petros, A.M.Hutchins, C.W.Panchal, S.C.Sun, C.Elmore, S.W.Shen, Y.Kati, W.M.McDaniel, K.F.

(2017) J Med Chem 60: 3828-3850

  • DOI: 10.1021/acs.jmedchem.7b00017
  • Primary Citation of Related Structures:  
    5UEU, 5UEW, 5UEX, 5UEY, 5UEZ, 5UF0

  • PubMed Abstract: 
  • Members of the BET family of bromodomain containing proteins have been identified as potential targets for blocking proliferation in a variety of cancer cell lines. A two-dimensional NMR fragment screen for binders to the bromodomains of BRD4 identified a phenylpyridazinone fragment with a weak binding affinity (1, K i = 160 μM) ...

    Members of the BET family of bromodomain containing proteins have been identified as potential targets for blocking proliferation in a variety of cancer cell lines. A two-dimensional NMR fragment screen for binders to the bromodomains of BRD4 identified a phenylpyridazinone fragment with a weak binding affinity (1, K i = 160 μM). SAR investigation of fragment 1, aided by X-ray structure-based design, enabled the synthesis of potent pyridone and macrocyclic pyridone inhibitors exhibiting single digit nanomolar potency in both biochemical and cell based assays. Advanced analogs in these series exhibited high oral exposures in rodent PK studies and demonstrated significant tumor growth inhibition efficacy in mouse flank xenograft models.


    Organizational Affiliation

    AbbVie Inc. , 1 North Waukegan Road, North Chicago, Illinois 60064, United States.



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Bromodomain-containing protein 4A109Homo sapiensMutation(s): 0 
Gene Names: BRD4HUNK1
UniProt & NIH Common Fund Data Resources
Find proteins for O60885 (Homo sapiens)
Explore O60885 
Go to UniProtKB:  O60885
PHAROS:  O60885
Protein Feature View
Expand
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
89G (Subject of Investigation/LOI)
Query on 89G

Download Ideal Coordinates CCD File 
B [auth A]5-methoxy-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one
C18 H16 N2 O3
MDTCYTNEBYQKFC-UHFFFAOYSA-N
 Ligand Interaction
Binding Affinity Annotations 
IDSourceBinding Affinity
89G BindingDB:  5UEZ Ki: 970 (nM) from 1 assay(s)
EC50: 3000 (nM) from 1 assay(s)
Binding MOAD:  5UEZ Ki: 970 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.51 Å
  • R-Value Free: 0.204 
  • R-Value Work: 0.182 
  • R-Value Observed: 0.183 
  • Space Group: P 21 21 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 57.982α = 90
b = 72.782β = 90
c = 33.654γ = 90
Software Package:
Software NamePurpose
SCALAdata scaling
XDSdata reduction
Cootmodel building
BUSTERrefinement

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment  



Entry History 

Deposition Data

  • Deposited Date: 2017-01-03 
  • Released Date: 2017-05-10 
  • Deposition Author(s): Park, C.H.

Revision History  (Full details and data files)

  • Version 1.0: 2017-05-10
    Type: Initial release
  • Version 1.1: 2017-05-24
    Changes: Database references